Search research articles
Contact Us
Filters
Showing results (221-230 of 241) with videos related to
Page
of 25
Sort By:
Cancer Research
|
January 10, 2002
Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients
Marc Ladanyi, Cristina R Antonescu, Denis H Leung, et al.
Nature Communications
|
February 10, 2016
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer
Pasquale Sansone, Claudio Ceccarelli, Marjan Berishaj, et al.
Science (New York, N.Y.)
|
February 26, 2026
Sensitive CAR T cells redefine targetable CD70 expression in solid tumors
Sophie A Hanina, Tyler Park, Michael Lopez, et al.
Biorxiv : the Preprint Server for Biology
|
November 14, 2023
Breast Cancer Macrophage Heterogeneity and Self-renewal are Determined by Spatial Localization
Nir Ben-Chetrit, Xiang Niu, Jesus Sotelo, et al.
Clinical Therapeutics
|
April 5, 2016
Patient-reported Symptoms of Tenosynovial Giant Cell Tumors
Heather L Gelhorn, Sandra Tong, Kelly McQuarrie, et al.
The Oncologist
|
October 10, 2015
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas
Rodrigo R Munhoz, Sandra P D'Angelo, Mrinal M Gounder, et al.
Lancet (London, England)
|
June 24, 2019
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
William D Tap, Hans Gelderblom, Emanuela Palmerini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
William D Tap, Arun S Singh, Stephen Patrick Anthony, et al.
NPJ Breast Cancer
|
May 25, 2021
Anti-tumor effects of an ID antagonist with no observed acquired resistance
Paulina M Wojnarowicz, Marta Garcia Escolano, Yun-Han Huang, et al.
European Urology Focus
|
July 30, 2017
Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples
Yiyu Dong, Brandon J Manley, Maria F Becerra, et al.
Page
of 25
Search research articles
Search
Showing results (221-230 of 241) with videos related to
Sort By:
Page
of 25
Cancer Research
|
January 10, 2002
Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients
Marc Ladanyi, Cristina R Antonescu, Denis H Leung, et al.
Nature Communications
|
February 10, 2016
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer
Pasquale Sansone, Claudio Ceccarelli, Marjan Berishaj, et al.
Science (New York, N.Y.)
|
February 26, 2026
Sensitive CAR T cells redefine targetable CD70 expression in solid tumors
Sophie A Hanina, Tyler Park, Michael Lopez, et al.
Biorxiv : the Preprint Server for Biology
|
November 14, 2023
Breast Cancer Macrophage Heterogeneity and Self-renewal are Determined by Spatial Localization
Nir Ben-Chetrit, Xiang Niu, Jesus Sotelo, et al.
Clinical Therapeutics
|
April 5, 2016
Patient-reported Symptoms of Tenosynovial Giant Cell Tumors
Heather L Gelhorn, Sandra Tong, Kelly McQuarrie, et al.
The Oncologist
|
October 10, 2015
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas
Rodrigo R Munhoz, Sandra P D'Angelo, Mrinal M Gounder, et al.
Lancet (London, England)
|
June 24, 2019
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
William D Tap, Hans Gelderblom, Emanuela Palmerini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
William D Tap, Arun S Singh, Stephen Patrick Anthony, et al.
NPJ Breast Cancer
|
May 25, 2021
Anti-tumor effects of an ID antagonist with no observed acquired resistance
Paulina M Wojnarowicz, Marta Garcia Escolano, Yun-Han Huang, et al.
European Urology Focus
|
July 30, 2017
Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples
Yiyu Dong, Brandon J Manley, Maria F Becerra, et al.
Page
of 25